Lexeo Therapeutics (LXEO) Non-Current Assets (2022 - 2026)

Lexeo Therapeutics has disclosed Non-Current Assets across 5 years of filings, most recently posting $49.5 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $49.5 million, up 142.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $181.8 million (up 157.93% YoY), and the FY2025 annual result was $80.3 million, up 285.65% from the prior year.
• Non-Current Assets came in at $49.5 million for Q1 2026 at Lexeo Therapeutics, down from $80.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $80.3 million in Q4 2025 to a low of $14.4 million in Q3 2024.
• The 5-year median for Non-Current Assets is $16.5 million (2022), against an average of $26.3 million.
• Across the five-year window, Non-Current Assets decreased 9.1% in 2024 and surged 285.65% in 2025, its largest moves.
• Lexeo Therapeutics' Non-Current Assets stood at $17.0 million in 2022, then fell by 8.9% to $15.5 million in 2023, then soared by 34.22% to $20.8 million in 2024, then soared by 285.65% to $80.3 million in 2025, then plunged by 38.36% to $49.5 million in 2026.
• The last three Non-Current Assets figures came in at $49.5 million (Q1 2026), $80.3 million (Q4 2025), and $16.1 million (Q3 2025), per Business Quant data.